Inovio falls as it drops to vaccine programs

18 November 2022

Shares of US biotech Inovio (Nasdaq: INO) were down almost 7% at $2.30, after the company disclosed it was halting development of two vaccine programs because of disappointing clinical trial results.

The company announced that it has agreed with its collaborator, non-profit organization the Coalition for Epidemic Preparedness Innovations (CEPI), to discontinue development of product candidates targeting Lassa fever (INO-4500) and Middle East respiratory syndrome (MERS) (INO-4700), following initial analyses of data from studies conducted by Inovio and funded by the CEPI.

Under a partnership signed in 2018, the CEPI had agreed to provide as much as $56 million to take the vaccines through Phase II.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK